biomedical sciences research institute - Research - University of Ulster

Publications:Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR; Effects of antidiabetic drugs on dipeptidylpeptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-likepeptide-1; European Journal of Pharmacology, 568: 278-286, 2007Gault VA, Hunter K, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Flatt PR; Characterisation and biological activityof Glu 3 amino acid substituted GIP receptor antagonists; Archives of Biochemistry Biophysics, 461: 263-274, 2007Gault VA, McClean PL, Irwin N, Power GJ, McCluskey JT, Flatt PR; Effects of subchronic treatment with the long-actingglucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocininduceddiabetes; Pancreas, 35: 73-79, 2007Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR; Chemical gastric inhibitory polypeptide receptor antagonismprotects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat andcafeteria diets; Diabetologia, 50: 1752-1762, 2007Green BD, Irwin N, Flatt PR; Direct and indirect effects of obestatin peptides on food intake and the regulation ofglucose homeostasis and insulin secretion in mice; Peptides, 28: 981-987, 2007Irwin N, McClean PL, Cassidy RS, O'Harte FP, Green BD, Gault VA, Harriott P, Flatt PR; Comparison of the antidiabeticeffects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistantN-AcGIP and exendin(1-39)amide; Diabetes Metabolism Research and Reviews, 23: 572-579, 2007Irwin N, Hunter K, Flatt PR; Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptoractivation in high fat fed mice; Peptides, 28: 2192-2198, 2007Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR; Early administration of the glucose-dependent insulinotropicpolypeptide receptor antagonist (Pro( 3 ))GIP prevents the development of diabetes and related metabolicabnormalities associated with genetically inherited obesity in ob/ob mice; Diabetologia, 50: 1532-1540, 2007Irwin N, McClean PL, Flatt PR; Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1analogues in obese diabetic (ob/ob) mice; Journal of Peptide Science, 13: 400-405, 2007Irwin N, McClean PL, Harriott P, Flatt PR; Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice; Experimental Gerontology,42: 296-300, 2007McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR; GIP receptor antagonism reverses obesity, insulin resistanceand associated metabolic disturbances induced in mice by prolonged consumption of high fat diet; AmericanJournal of Physiology Endocrinology and Metabolism, 293: E1746-1755, 2007O'Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR; Antagonistic effects oftwo novel GIP analogues, (Hyp 3 )GIP and (Hyp 3 )GIPLys 16 PAL on the biological actions of GIP and longer term effectsin diabetic ob/ob mice; American Journal of Physiology Endocrinology and Metabolism, 292: E1674-1682, 2007Gault VA, Kerr BD, Irwin N, Flatt PR; C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptideexhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes; Biochemical Pharmacology,75: 2325-2333, 2008Irwin N, McClean PL, Hunter K, Gault VA & Flatt PR (Pro 3 )GIP[mPEG]: Novel long-acting mini-PEGylated gastricinhibitory polypeptide antagonist for obesity-diabetes therapy; British Journal of Pharmacology, 155: 690-701, 2008Irwin N, Hunter K, Flatt PR; Comparison of independent and combined chronic metabolic effects of GIP and CB 1receptor blockade in high-fat fed mice; Peptides, 29: 1036-1041, 200854